Literature DB >> 8902977

Intramedullary cysticercosis cured with drug treatment. A case report.

I Corral1, C Quereda, A Moreno, R López-Vélez, J Martínez-San-Millán, A Guerrero, J Sotelo.   

Abstract

STUDY
DESIGN: A report of a patient with cervical intramedullary cysticercosis is presented.
OBJECTIVES: To report the first case of intramedullary. cysticercosis cured with drug management only, which supports the hypothesis that management with anthelmintics might be successfully used in this form of cysticercosis. SUMMARY OF BACKGROUND DATA: Intramedullary cysticercosis is a rare manifestation of neurocysticercosis. Every treated patient reported to date has undergone surgery, frequently necessary for diagnosis. Since the anthelmintics praziquantel and albendazole were shown to be effective in parenchymal brain cysticercosis, these drugs have been considered potentially useful in patients with intramedullary cysticercosis. Nevertheless, no case yet had been reported to be cared with only medical therapy.
METHODS: The treatment of a patient who suffered multiple cysticercal reinfestations of the nervous system is presented.
RESULTS: The patient received prolonged treatment with albendazole because of superimposed cerebral reinfestations. During this treatment, she suffered acute paraparesis, and cervical magnetic resonance imaging showed cyst-like lesions with linear gadolinium enhancement and perilesional edema, indicative of dying cysticerci and inflammatory host reaction. Dexamethasone was added, and progressive neurologic improvement followed with complete resolution of intramedullary lesions.
CONCLUSIONS: A preoperative diagnostic suspicion of cysticercosis is important in patients with intramedullary cystic lesions because specific drug treatment is available. Treatment with anthelmintics, particularly albendazole, should be considered in patients with intramedullary cysticercosis before surgery. Corticosteroids may be added to the therapeutic regimen because this may reduce the perilesional edema and prevent neurologic deterioration during the course of anthelmintic treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902977     DOI: 10.1097/00007632-199610010-00023

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  16 in total

Review 1.  Spinal Taenia solium cysticercosis in Mexican and Indian patients: a comparison of 30-year experience in two neurological referral centers and review of literature.

Authors:  Graciela Cárdenas; Erik Guevara-Silva; Felipe Romero; Yair Ugalde; Cecilia Bonnet; Agnes Fleury; Edda Sciutto; Caris Maroni Nunes; José Luis Soto-Hernández; Susarla Krishna Shankar; Anita Mahadevan
Journal:  Eur Spine J       Date:  2015-10-16       Impact factor: 3.134

2.  Lumbar intradural neurocysticercosis: a case report.

Authors:  Sang-Beom Han; Hyon-Jo Kwon; Seung-Won Choi; Hyeon-Song Koh; Seon-Hwan Kim; Shi-Hun Song; Jin-Young Youm
Journal:  Korean J Spine       Date:  2014-09-30

3.  Intramedullary spinal cysticercosis: a case report and review of literature.

Authors:  Moinay Kim; Seung Chul Rhim; Shin-Kwang Khang
Journal:  Korean J Spine       Date:  2014-06-30

4.  Neurocysticercosis: an update.

Authors:  Christina M Coyle
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

Review 5.  Extraparenchymal (Racemose) Neurocysticercosis and Its Multitude Manifestations: A Comprehensive Review.

Authors:  Rohan R Mahale; Anish Mehta; Srinivasa Rangasetty
Journal:  J Clin Neurol       Date:  2015-05-28       Impact factor: 3.077

6.  Multilevel intramedullary spinal neurocysticercosis with eosinophilic meningitis.

Authors:  Amir M Torabi; Mary Quiceno; Dianne B Mendelsohn; Craig M Powell
Journal:  Arch Neurol       Date:  2004-05

Review 7.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 8.  Epidemiology and management of cysticercosis and Taenia solium taeniasis in Europe, systematic review 1990-2011.

Authors:  Lorenzo Zammarchi; Marianne Strohmeyer; Filippo Bartalesi; Elisa Bruno; José Muñoz; Dora Buonfrate; Alessandra Nicoletti; Héctor Hugo García; Edoardo Pozio; Alessandro Bartoloni
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

Review 9.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 10.  Neurocysticercosis in children.

Authors:  Pratibha Singhi; Sunit Singhi
Journal:  Indian J Pediatr       Date:  2009-05-24       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.